Image Place holder

Frederick Locke, MD


Specialty: Medical Oncology
Program: Blood and Marrow Transplant and Cellular Immunotherapy

Call 1-888-MOFFITT
(1-888-663-3488)

or call 1-888-MOFFITT
(1-888-663-3488)

Overview

Dr. Locke is a medical oncologist and translational researcher in the Department of Blood and Marrow Transplant and Cellular Immunotherapy. He leads the Immune Cell Therapy (ICE-T) initiative at Moffitt, an integrated cross-departmental translational team. Dr. Locke is a clinical research leader in the field of Chimeric Antigen Receptor (CAR) T cell therapy, acting as a national P.I. for several pivotal trials of anti-CD19 CARs for lymphoma. In addition, Dr. Locke is translating findings from his laboratory into new cellular immunotherapies such as the Moffitt created whole protein survivin tumor vaccine for multiple myeloma. Dr. Locke graduated with a B.S. in Physiology from Michigan State University, and with an M.D. from Wayne State University. He stayed at Wayne State and the Detroit Medical Center for Internal Medicine residency training and then served as Chief Medical Resident at Detroit Receiving. Dr. Locke received Medical Oncology, clinical research, and laboratory research training at the University of Chicago.  Dr. Locke provides care for multiple myeloma, lymphoma, and leukemia patients. He oversees both autologous and allogeneic hematopoietic stem cell transplants as well as cellular immunotherapy treatments such as CAR T cell Therapy.

Education & Training

Board Certification:

  • Medical Oncology

Fellowship:

  • University of Chicago Medical Center - Hematology/Oncology

Residency:

  • Wayne State University/Detroit Medical Center - Internal Medicine

Medical School:

  • Wayne State University - MD
Participating Trials

CLINICAL TRIAL 17967
A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)
Condition: Malignant Hematology
Intervention: Axicabtagene Ciloleucel (KTE-C19); KTE-C19; Levetiracetam; Tocilizumab; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 18346
Evaluating the Safety and Biological Activity of a Dendritic Cell Survivin Vaccine in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplantation
Condition: Malignant Hematology
Intervention: G-CSF; Prevnar13; Survivin-Dendritic Cell Vaccine
Open

CLINICAL TRIAL 18816
A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Combination with Atezolizumab in Subjects with Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Condition: Malignant Hematology
Intervention: Atezolizumab (Tecentriq); Axicabtagene Ciloleucel (KTE-C19); KTE-C19; Not Applicable; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 18289
A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)
Condition: Malignant Hematology
Intervention: Axicabtagene Ciloleucel (KTE-C19); KTE-C19
Open

CLINICAL TRIAL 17790
A Randomized Phase II Study of Autologous Stem Cell Transplantation with Tadalafil and Lenalidomide Maintenance with or without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma
Condition: Malignant Hematology
Intervention: Alkeran (Melphalan); CC-5013 (Lenalidomide); Lenalidomide (Revlimid); Marrow Infiltrating Lymphocytes (MILs); Melphalan; Tadalafil
Open

CLINICAL TRIAL 18950
A Phase I/Ib Study of Ipilimumab or Nivolumab in Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation
Condition: Malignant Hematology
Intervention: BMS-936558 (Nivolumab); Nivolumab
Open

CLINICAL TRIAL 19070
A Multicenter, Open-label, Expanded Access Study of Axicabtagene Ciloleucel for the Treatment of Relapsed/Refractory Transplant-Ineligible Aggressive Non-Hodgkin Lymphoma (NHL)
Condition: Malignant Hematology
Intervention: Axicabtagene Ciloleucel (KTE-C19); cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 17263
Phase I Trial of ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-Versus-Host Disease
Condition: Malignant Hematology
Intervention: FK506 (Tacrolimus); Rapamune (Sirolimus); Rapamycin (Sirolimus); Sirolimus; Tacrolimus
Open

CLINICAL TRIAL 17676
A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Age 50 or Older with Intermediate-2 and High Risk Myelodysplastic Syndrome
Condition: Malignant Hematology
Intervention:
Open

CLINICAL TRIAL 18331
Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes
Condition: Malignant Hematology
Intervention:
Open

CLINICAL TRIAL 18329
A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL)
Condition: Malignant Hematology
Intervention: Axicabtagene Ciloleucel (KTE-C19); KTE-C19; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 18430
Evaluation of Panobinostat (LBH589) as Maintenance Therapy in Multiple Myeloma Following Autologous Hematopoietic Cell Transplantation
Condition: Malignant Hematology
Intervention: Panobinostat (LBH589)
Open

CLINICAL TRIAL 18374
A Phase II Trial Evaluating the use of a Histone Deacetylase Inhibitor Panobinostat for Graft Versus Host Disease (GVHD) Prevention
Condition: Malignant Hematology
Intervention: Not Applicable; Panobinostat (LBH589)
Open

CLINICAL TRIAL 18814
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies
Condition: Malignant Hematology
Intervention: busulfan; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 18217
Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma
Condition: Malignant Hematology
Intervention: Alkeran (Melphalan); Bortezomib; FK506 (Tacrolimus); Ixazomib (Ninlaro); Melphalan; Not Applicable; PS-341 (Bortezomib); Placebo; Tacrolimus; Velcade (Bortezomib); fludarabine (Fludarabine phosphate); methotrexate
Open

CLINICAL TRIAL 18766
A Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haploidentical Peripheral Blood Stem Cell Transplantation
Condition: Malignant Hematology
Intervention: Cellcept (Mycophenolate Mofetil); Mycophenolate Mofetil; Rapamune (Sirolimus); Rapamycin (Sirolimus); Sirolimus; busulfan; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 18664
A Phase 2, Multi-Center Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin for the Treatment of T cell Non-Hodgkin's Lymphoma
Condition: Malignant Hematology
Intervention: Alkeran (Melphalan); Carmustine; Cytarabine (Cytosine Arabinoside); FK228 (Romidepsin); Melphalan; Romidepsin; etoposide
Open

CLINICAL TRIAL 18763
A Randomized, Phase II, Multicenter, Open Label, Study Evaluating Sirolimus and Prednisone in Patients with Refined Minnesota Standard Risk, Ann Arbor 1/2 Confirmed Acute Graft-Versus-Host Disease
Condition: Malignant Hematology
Intervention: Rapamune (Sirolimus); Rapamycin (Sirolimus); Sirolimus; prednisone
Open

CLINICAL TRIAL 18783
A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression
Condition: Malignant Hematology
Intervention: Alkeran (Melphalan); FK506 (Tacrolimus); Melphalan; Pacritinib; Rapamune (Sirolimus); Rapamycin (Sirolimus); Sirolimus; Tacrolimus; busulfan; fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 18938
A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*0401 Positive Subjects with Advanced Cancers
Condition: Multiple
Intervention: Aldesleukin (Interleukin-2); IL-2 (Interleukin-2); Interleukin-2; KITE-718; MESNA; Proleukin (Interleukin-2); cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 18959
A Phase 2 Study to Evaluate the Safety, Tolerability and Efficacy of Cell Transfer Therapy Using Autologous Tumor Infiltrating Lymphocytes (LN-145) followed by IL-2 in Patients with Recurrent and/or Metastatic Cervical Carcinoma
Condition: Gynecological Tumor
Intervention: Fluconazole; IL-2 (Interleukin-2); LN-145; MESNA; Neupogen (filgrastim); cyclophosphamide; cytoxan (cyclophosphamide); filgrastim; fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 19072
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
Condition: Malignant Hematology
Intervention: Axicabtagene Ciloleucel (KTE-C19); cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 18626
Carfilzomib for Treatment of Chronic Graft vs. Host Disease
Condition: Malignant Hematology
Intervention: carfilzomib (Kyprolis)
Open

CLINICAL TRIAL 19093
Open-Label Randomized Pilot Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered NY-ESO-1 Specific (c259) T Cells Alone or in Combination with Pembrolizumab in HLA-A2+ Subjects with NY-ESO-1 and/or LAGE-1a Positive Relapsed and Refractory Multiple Myeloma
Condition: Malignant Hematology
Intervention: NY-ESO-1c259T; Pembrolizumab (Keytruda); cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 19089
Optimizing Cord Blood and Haploidentical Aplastic Anemia Transplantation (CHAMP)
Condition: Malignant Hematology
Intervention: Thymoglobulin; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 19119
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease
Condition: Malignant Hematology
Intervention: Jakafi (Ruxolitinib); Methylprednisolone; Ruxolitinib; prednisone
Open

CLINICAL TRIAL 18964
Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of the Activated B-cell Subtype
Condition: Malignant Hematology
Intervention: 748645 (Ibrutinib); Ibrutinib (Imbruvica); PCI-32765 (Ibrutinib); Placebo
Open

CLINICAL TRIAL 19143
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus Host-Disease
Condition: Malignant Hematology
Intervention: ATG; Alkeran (Melphalan); FK506 (Tacrolimus); MESNA; Melphalan; Tacrolimus; busulfan; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate); methotrexate
Open

CLINICAL TRIAL 18930
A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients with Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)
Condition: Malignant Hematology
Intervention: AMG103 (Blinatumomab); Blinatumomab; CC-5013 (Lenalidomide); Lenalidomide (Revlimid)
Open

CLINICAL TRIAL 19203
Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease
Condition: Malignant Hematology
Intervention: Cellcept (Mycophenolate Mofetil); Hydroxyurea (Droxia); MESNA; Mycophenolate Mofetil; Radiotherapy; Rapamune (Sirolimus); Rapamycin (Sirolimus); Sirolimus; Thiotepa (Thioplex); Thymoglobulin; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).

Publications

  • Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2017 Sep. Pubmedid: 28925994.
  • Kharfan-Dabaja MA, Kumar A, Stingo FE, Khimani F, Hussaini M, Ayala E, Nishihori T, Shah B, Locke FL, Pinilla-Ibarz J, Chavez JC. Allogeneic Hematopoietic Cell Transplantation for Richter Syndrome: A Single-Center Experience. Clin Lymphoma Myeloma Leuk. 2017 Oct. Pubmedid: 29126867.
  • Murthy HS, Sheets K, Kumar A, Nishihori T, Mina A, Chavez JC, Ayala E, Field T, Mathews J, Locke F, Perez L, Betts BC, Khimani F, Miladinovic B, Tsalatsanis A, Ochoa-Bayona JL, Alsina M, Fernandez H, Pidala J, Anasetti C, Kharfan-Dabaja MA. Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients: A Confirmatory Study. Biol Blood Marrow Tr. 2017 Oct. Pubmedid: 29032266.
  • Chavez J, Locke FL. A Possible Cure for Refractory DLBCL: CARs Are Headed in the Right Direction. Mol Ther. 2017 Oct;25(10):2241-2243. Pubmedid: 28941574. Pmcid: PMC5628929.
  • Betts BC, Pidala J, Kim J, Mishra A, Nishihori T, Perez L, Ochoa-Bayona JL, Khimani F, Walton K, Bookout R, Nieder M, Khaira DK, Davila M, Alsina M, Field T, Ayala E, Locke FL, Riches M, Kharfan-Dabaja M, Fernandez H, Anasetti C. IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation. Haematologica. 2017 May;102(5):948-957. Pubmedid: 28104702. Pmcid: PMC5477614.
  • Locke FL, Pidala J, Storer B, Martin PJ, Pulsipher MA, Chauncey TR, Jacobsen N, Kröger N, Walker I, Light S, Shaw BE, Beato F, Laport GG, Nademanee A, Keating A, Socie G, Anasetti C. CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Tr. 2017 Mar;23(3):405-411. Pubmedid: 28007665.
  • Locke FL, Davila ML. Regulatory challenges and considerations for the clinical application of CAR-T cell anti-cancer therapy. Expert Opin Biol Ther. 2017 Jun;17(6):659-661. Pubmedid: 28454503.
  • Locke FL, Anasetti C. Transplanters drive CARs to the clinic by brewing ICE-T: the Moffitt roadmap. J Immunother Cancer. 2017 Jul;5:59. Pubmedid: 28725432. Pmcid: PMC5514522.
  • Khimani F, Kim J, Chen L, Dean E, Rizk V, Betts B, Nishihori T, Locke F, Mishra A, Perez L, Ayala E, Kharfan-Dabaja M, Nieder M, Fernandez H, Anasetti C, Pidala J. Predictors of overall survival among patients treated with sirolimus/tacrolimus vs methotrexate/tacrolimus for GvHD prevention. Bone Marrow Transplant. 2017 Jul;52(7):1003-1009. Pubmedid: 28368376.
  • Locke FL, Anasetti C. Transplanters drive CARs to the clinic by brewing ICE-T: the Moffitt roadmap. J Immunother Cancer. 2017 Jul;5(1):59. Pubmedid: 28716155. Pmcid: PMC5514522.
  • Hampras SS, Locke FL, Chavez JC, Patel NS, Giuliano AR, Miller K, Gheit T, Tommasino M, Rollison DE. Prevalence of cutaneous viral infections in incident cutaneous squamous cell carcinoma detected among chronic lymphocytic leukemia and hematopoietic stem cell transplant patients. Leuk Lymphoma. 2017 Jul;1-7. Pubmedid: 28679298.
  • Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, Ghobadi A, Budde LE, Bot A, Rossi JM, Jiang Y, Xue AX, Elias M, Aycock J, Wiezorek J, Go WY. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. Mol Ther. 2017 Jan;25(1):285-295. Pubmedid: 28129122. Pmcid: PMC5363293.
  • Locke FL. Highlights in Aggressive Non-Hodgkin Lymphoma From the 2017 American Society of Clinical Oncology Annual Meeting: Commentary. Clin Adv Hematol Oncol. 2017 Aug;15 Suppl 8(8):16-19. Pubmedid: 28837125.
  • Tees MT, Betts B, Hillgruber R, Ayala E, Field T, Kharfan-Dabaja MA, Locke F, Mishra A, Nishihori T, Ochoa-Bayona JL, Perez L, Pidala J, Anasetti C, Fernandez H, Riches ML. New sources for argument: do HLA-C and HLA disparity in adult double umbilical cord blood transplants predict outcomes?. Bone Marrow Transplant. 2016 Sep;51(9):1256-1258. Pubmedid: 27088383.
  • Locke FL, Menges M, Nishihori T, Nwoga C, Alsina M, Anasetti C. Boosting humoral and cellular immunity to pneumococcus by vaccination before and just after autologous transplant for myeloma. Bone Marrow Transplant. 2016 Feb;51:291-294. Pubmedid: 26457911.
  • Khimani F, Jeong DK, Miladinovic B, Nishihori T, Ayala E, Locke F, Mishra A, Chavez J, Shah B, Gage K, Kharfan-Dabaja MA. Nonfluorodeoxyglucose-Avid Persistent Splenomegaly at Time of Transplantation Delays Neutrophil and Platelets Engraftment without Affecting Survival in Patients with Lymphomas Undergoing Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Tr. 2016 Dec;22(12):2201-2207. Pubmedid: 27660169.
  • Chavez JC, Piris-Villaespesa M, Dalia S, Powers J, Turba E, Nodzon L, Komrokji R, Sokol L, Locke FL, Lancet J, Sotomayor EM, Kharfan-Dabaja MA, Pinilla-Ibarz J. Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia. Leuk Res. 2016 Aug;47:78-83. Pubmedid: 27285853.
  • Nelson R, Shapiro JF, Perkins JB, Kim J, Nishihori T, Pidala J, Ayala E, Locke FL, Field T, Mishra A, Riches M, Betts B, Perez L, Yue B, Ochoa-Bayona JL, Alsina M, Fernandez H, Anasetti C, Kharfan-Dabaja MA. Sirolimus, tacrolimus and antithymocyte globulin as GVHD prophylaxis in HLA-mismatched unrelated donor hematopoietic cell transplantation: a single institution experience. Bone Marrow Transplant. 2015 Nov;50(11):1487-1489. Pubmedid: 26301969. Pmcid: PMC4863975.
  • Locke FL, Menges M, Veerapathran A, Coppola D, Gabrilovich D, Anasetti C. Survivin-specific CD4+ T cells are decreased in patients with survivin-positive myeloma. J Immunother Cancer. 2015 May;3:20. Pubmedid: 25992291. Pmcid: PMC4437443.
  • Pidala J, Kim J, Betts BC, Alsina M, Ayala E, Fernandez HF, Field T, Kharfan-Dabaja MA, Locke FL, Mishra A, Nishihori T, Ochoa-Bayona L, Perez L, Riches M, Anasetti C. Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results. Biol Blood Marrow Tr. 2015 Jun;21(6):1074-1082. Pubmedid: 25805300.
  • Ayala E, Figueroa J, Perkins J, Kim J, Yue B, Riches M, Nishihori T, Locke F, Anasetti C, Kharfan-Dabaja MA. Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2015 Jun;15(6):335-340. Pubmedid: 25659459.
  • Zimmerman A, Locke FL, Emole J, Rosa M, Horna P, Hoover S, Dayicioglu D. Recurrent Systemic Anaplastic Lymphoma Kinase-Negative Anaplastic Large Cell Lymphoma Presenting as a Breast Implant-Associated Lesion. Cancer Control. 2015 Jul;22(3):369-373. Pubmedid: 26351895.
  • Pidala J, Kim J, Alsina M, Ayala E, Betts BC, Fernandez HF, Field T, Jim H, Kharfan-Dabaja MA, Locke FL, Mishra A, Nishihori T, Ochoa-Bayona L, Perez L, Riches M, Anasetti C. Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease. Haematologica. 2015 Jul;100(7):970-977. Pubmedid: 25840599. Pmcid: PMC4486232.
  • Locke FL, Rollison DE, Sondak VK. Merkel cell carcinoma and immunosuppression: what we still need to know. J Natl Cancer Inst. 2015 Feb;107(2). Pubmedid: 25575646.
  • Emole JN, Locke FL, Pinilla-Ibarz J. An update on current and prospective immunotherapies for chronic lymphocytic leukemia. Immunotherapy. 2015 Apr;7(4):455-466. Pubmedid: 25917633.
  • Chavez JC, Kharfan-Dabaja MA, Kim J, Yue B, Dalia S, Pinilla-Ibarz J, Anasetti C, Locke FL. Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia. Leuk Res. 2014 Oct;38(10):1165-1172. Pubmedid: 24889511. Pmcid: PMC4625795.
  • Kunter G, Perkins JB, Pidala J, Nishihori T, Kharfan-Dabaja MA, Field T, Fernandez H, Perez L, Locke F, Ayala E, Tomblyn M, Ochoa-Bayona JL, Betts B, Nieder M, Anasetti C. Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission. Bone Marrow Transplant. 2014 Jan;49(1):11-16. Pubmedid: 23995098.
  • Locke FL, Nishihori T, Alsina M, Kharfan-Dabaja MA. Immunotherapy strategies for multiple myeloma: the present and the future. Immunotherapy. 2013 Sep;5(9):1005-1020. Pubmedid: 23998734. Pmcid: PMC4905571.
  • Pidala J, Kim J, Schell M, Lee SJ, Hillgruber R, Nye V, Ayala E, Alsina M, Betts B, Bookout R, Fernandez HF, Field T, Locke FL, Nishihori T, Ochoa JL, Perez L, Perkins J, Shapiro J, Tate C, Tomblyn M, Anasetti C. Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization. Bone Marrow Transplant. 2013 Mar;48(3):346-350. Pubmedid: 22863723. Pmcid: PMC4500122.
  • Kharfan-Dabaja MA, Anasetti C, Fernandez HF, Perkins J, Ochoa-Bayona JL, Pidala J, Perez LE, Ayala E, Field T, Alsina M, Nishihori T, Locke F, Pinilla-Ibarz J, Tomblyn M. Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting. Biol Blood Marrow Tr. 2013 Jul;19(7):1087-1093. Pubmedid: 23632090. Pmcid: PMC4667782.
  • Locke FL, Zha YY, Zheng Y, Driessens G, Gajewski TF. Conditional deletion of PTEN in peripheral T cells augments TCR-mediated activation but does not abrogate CD28 dependency or prevent anergy induction. J Immunol. 2013 Aug;191(4):1677-1685. Pubmedid: 23851688. Pmcid: PMC3759681.
  • Zheng Y, Zha Y, Driessens G, Locke F, Gajewski TF. Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo. J Exp Med. 2012 Nov;209(12):2157-2163. Pubmedid: 23129747. Pmcid: PMC3501351.
  • Pidala J, Kim J, Jim H, Kharfan-Dabaja MA, Nishihori T, Fernandez HF, Tomblyn M, Perez L, Perkins J, Xu M, Janssen WE, Veerapathran A, Betts BC, Locke FL, Ayala E, Field T, Ochoa L, Alsina M, Anasetti C. A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. Haematologica. 2012 Dec;97(12):1882-1889. Pubmedid: 22689677. Pmcid: PMC3590095.
  • Locke FL, Morgan GJ. What is the evidence for the use of bisphosphonate therapy in newly diagnosed multiple myeloma patients lacking bone disease?. Hematology Am Soc Hematol Educ Program. 2012 Dec;2012:350-353. Pubmedid: 23233603.
  • Pidala J, Tomblyn M, Nishihori T, Field T, Ayala E, Perkins J, Fernandez H, Locke F, Perez L, Ochoa JL, Alsina M, Anasetti C. Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids. Haematologica. 2011 Sep;96(9):1351-1356. Pubmedid: 21565902. Pmcid: PMC3166106.
  • Pidala J, Tomblyn M, Nishihori T, Ayala E, Field T, Fernandez H, Perez L, Locke F, Alsina M, Ochoa JL, Perkins J, Tate C, Shapiro J, Conwell M, Bookout R, Anasetti C. ATG prevents severe acute graft-versus-host disease in mismatched unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Tr. 2011 Aug;17(8):1237-1244. Pubmedid: 21215811.
  • Locke F, Clark JI, Gajewski TF. A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanoma. Cancer Chemother Pharmacol. 2010 Feb;65(3):509-514. Pubmedid: 19597729.
  • Locke FL, Artz A, Rich E, Zhang Y, van Besien K, Stock W. Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML. Bone Marrow Transplant. 2010 Dec;45(12):1692-1698. Pubmedid: 20208570.
  • Zha Y, Shah R, Locke F, Wong A, Gajewski TF. Use of Cre-adenovirus and CAR transgenic mice for efficient deletion of genes in post-thymic T cells. J Immunol Methods. 2008 Feb;331(1-2):94-102. Pubmedid: 18177887. Pmcid: PMC3278801.
  • Mattison RJ, Ostler KR, Locke FL, Godley LA. Implications of FLT3 mutations in the therapy of acute myeloid leukemia. Rev Recent Clin Trials. 2007 May;2(2):135-141. Pubmedid: 18473998.